ArticleAntimicrobial agents and chemotherapy2017
Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The anti-Leishmania potential of bioactive compounds derived from naphthoquinones and their possible applications. A systematic review of animal studies.Parasitology research · 2022Pooled it
- Article
- Synthesis of a dehydrodieugenol B derivative as a lead compound for visceral leishmaniasis-mechanism of action andAntimicrobial agents and chemotherapy · 2024Article
- Can letrozole be repurposed for the treatment of visceral leishmaniasis?Antimicrobial agents and chemotherapy · 2024Article
- Modulation of CXCL10 activity as a therapeutic target of ocular toxoplasmosis in diabetic mice.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Article
- Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review.Beilstein journal of nanotechnology · 2024Review
- Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions ofFrontiers in cellular and infection microbiology · 2023Article
- Metabolic Pathways ofPharmaceutics · 2022Review
- Article
- Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.PLoS neglected tropical diseases · 2021Article
- Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.ACS biomaterials science & engineering · 2021Review
- Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis.Frontiers in cellular and infection microbiology · 2019Article
- Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases.The journal of venomous animals and toxins including tropical diseases · 2019Article
- Targeting Channels and Transporters in Protozoan Parasite Infections.Frontiers in chemistry · 2018Review
- The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis is a fatal parasitic neglected disease affecting 1.5 million people worldwide. Based on a drug repositioning approach, the aim of this work was to investigate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.